SG11202005868XA - Mtor inhibitor compounds - Google Patents
Mtor inhibitor compoundsInfo
- Publication number
- SG11202005868XA SG11202005868XA SG11202005868XA SG11202005868XA SG11202005868XA SG 11202005868X A SG11202005868X A SG 11202005868XA SG 11202005868X A SG11202005868X A SG 11202005868XA SG 11202005868X A SG11202005868X A SG 11202005868XA SG 11202005868X A SG11202005868X A SG 11202005868XA
- Authority
- SG
- Singapore
- Prior art keywords
- mtor inhibitor
- inhibitor compounds
- compounds
- mtor
- inhibitor
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
- 229940124302 mTOR inhibitor Drugs 0.000 title 1
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/20—Spiro-condensed systems
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1771402A FR3075795A1 (fr) | 2017-12-21 | 2017-12-21 | Nouveaux composes inhibiteurs de mtor |
| PCT/EP2018/086074 WO2019122065A1 (fr) | 2017-12-21 | 2018-12-20 | Composes inhibiteurs de mtor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202005868XA true SG11202005868XA (en) | 2020-07-29 |
Family
ID=62017455
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202005868XA SG11202005868XA (en) | 2017-12-21 | 2018-12-20 | Mtor inhibitor compounds |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US11518767B2 (es) |
| EP (1) | EP3727390B1 (es) |
| JP (1) | JP2021506917A (es) |
| KR (1) | KR20200103032A (es) |
| CN (1) | CN111918654A (es) |
| AU (1) | AU2018392761B2 (es) |
| BR (1) | BR112020012201A2 (es) |
| CA (1) | CA3086243A1 (es) |
| CL (1) | CL2020001686A1 (es) |
| FR (1) | FR3075795A1 (es) |
| IL (1) | IL275531B2 (es) |
| MX (1) | MX2020006436A (es) |
| RU (1) | RU2020123899A (es) |
| SA (1) | SA520412289B1 (es) |
| SG (1) | SG11202005868XA (es) |
| WO (1) | WO2019122065A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110407703A (zh) * | 2019-08-02 | 2019-11-05 | 深圳振强生物技术有限公司 | 吲哚布芬杂质的制备方法 |
| WO2023285926A1 (en) | 2021-07-12 | 2023-01-19 | Galderma Holding SA | Synthesis of chiral substituted pyrazolopyrimidine compounds |
| WO2023031738A1 (en) | 2021-08-31 | 2023-03-09 | Galderma Holding SA | Novel mtor inhibitor compounds |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20060070572A (ko) | 2003-09-18 | 2006-06-23 | 콘포마 세러퓨틱스 코포레이션 | Ｈｓｐ90-저해제로서의 신규 헤테로시클릭 화합물 |
| EP2385053B1 (en) * | 2005-11-17 | 2013-10-02 | OSI Pharmaceuticals, Inc. | Intermediates for the preparation of fused bicyclic mTOR inhibitors |
| US20100331297A1 (en) | 2007-11-07 | 2010-12-30 | Foldrx Pharmaceuticals, Inc. | Modulation of protein trafficking |
| KR20110017845A (ko) | 2008-03-19 | 2011-02-22 | 오에스아이 파마슈티컬스, 인코포레이티드 | Ｍｔｏｒ 억제자 염 형태 |
| US9295673B2 (en) | 2011-02-23 | 2016-03-29 | Intellikine Llc | Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof |
| JP6047149B2 (ja) * | 2011-05-04 | 2016-12-21 | インテリカイン， エルエルシー | 併用の医薬組成物およびその使用 |
| EP2704723A4 (en) * | 2011-05-06 | 2014-12-24 | Univ California | TREATMENT OF POLYCYSTIC DISEASES |
| US9242993B2 (en) * | 2011-10-07 | 2016-01-26 | Cellzome Limited | Morpholino substituted bicyclic pyrimidine urea or carbamate derivatives as mTOR inhibitors |
| WO2013078440A2 (en) | 2011-11-23 | 2013-05-30 | Intellikine, Llc | Enhanced treatment regimens using mtor inhibitors |
| CA2833701A1 (en) * | 2013-11-19 | 2015-05-19 | Pharmascience Inc. | Protein kinase inhibitors |
| WO2017186760A1 (en) * | 2016-04-29 | 2017-11-02 | Merck Patent Gmbh | Materials for organic electroluminescent devices |
| FR3075794A1 (fr) | 2017-12-21 | 2019-06-28 | Galderma Research & Development | Nouveaux composes inhibiteurs de mtor |
-
2017
- 2017-12-21 FR FR1771402A patent/FR3075795A1/fr active Pending
-
2018
- 2018-12-20 WO PCT/EP2018/086074 patent/WO2019122065A1/fr unknown
- 2018-12-20 EP EP18826025.1A patent/EP3727390B1/fr active Active
- 2018-12-20 AU AU2018392761A patent/AU2018392761B2/en active Active
- 2018-12-20 CA CA3086243A patent/CA3086243A1/en active Pending
- 2018-12-20 CN CN201880090046.3A patent/CN111918654A/zh active Pending
- 2018-12-20 JP JP2020534447A patent/JP2021506917A/ja not_active Ceased
- 2018-12-20 RU RU2020123899A patent/RU2020123899A/ru unknown
- 2018-12-20 MX MX2020006436A patent/MX2020006436A/es unknown
- 2018-12-20 KR KR1020207020410A patent/KR20200103032A/ko not_active Application Discontinuation
- 2018-12-20 IL IL275531A patent/IL275531B2/en unknown
- 2018-12-20 BR BR112020012201-7A patent/BR112020012201A2/pt unknown
- 2018-12-20 SG SG11202005868XA patent/SG11202005868XA/en unknown
-
2020
- 2020-06-19 US US16/907,122 patent/US11518767B2/en active Active
- 2020-06-19 CL CL2020001686A patent/CL2020001686A1/es unknown
- 2020-06-21 SA SA520412289A patent/SA520412289B1/ar unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3727390B1 (fr) | 2023-03-22 |
| AU2018392761B2 (en) | 2023-09-14 |
| MX2020006436A (es) | 2020-09-17 |
| FR3075795A1 (fr) | 2019-06-28 |
| IL275531B2 (en) | 2023-09-01 |
| US11518767B2 (en) | 2022-12-06 |
| IL275531A (en) | 2020-08-31 |
| SA520412289B1 (ar) | 2022-07-28 |
| JP2021506917A (ja) | 2021-02-22 |
| IL275531B1 (en) | 2023-05-01 |
| AU2018392761A1 (en) | 2020-07-09 |
| CN111918654A (zh) | 2020-11-10 |
| WO2019122065A1 (fr) | 2019-06-27 |
| KR20200103032A (ko) | 2020-09-01 |
| EP3727390A1 (fr) | 2020-10-28 |
| CL2020001686A1 (es) | 2020-11-27 |
| CA3086243A1 (en) | 2019-06-27 |
| BR112020012201A2 (pt) | 2020-11-24 |
| RU2020123899A3 (es) | 2022-02-17 |
| RU2020123899A (ru) | 2022-01-21 |
| US20200317683A1 (en) | 2020-10-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL275365A (en) | 6-Azaindole compounds | |
| IL275344A (en) | 4-azaindole compounds | |
| GB201700814D0 (en) | Compounds | |
| GB201705971D0 (en) | Inhibitor compounds | |
| GB201403536D0 (en) | Inhibitor compounds | |
| IL275532A (en) | MTOR inhibitory compounds | |
| GB201513481D0 (en) | Inhibitor compounds | |
| GB201505658D0 (en) | Inhibitor compounds | |
| GB201819126D0 (en) | Inhibitor compounds | |
| IL275531B1 (en) | mtor inhibitory compounds | |
| GB201702221D0 (en) | Compounds | |
| GB201720145D0 (en) | Inhibitor compounds | |
| GB201708507D0 (en) | Inhibitor compounds | |
| GB201708510D0 (en) | Inhibitor compounds | |
| GB201708502D0 (en) | Inhibitor compounds | |
| GB201819136D0 (en) | Inhibitor compounds | |
| GB201705968D0 (en) | Inhibitor compounds | |
| GB201806131D0 (en) | Inhibitor compounds | |
| GB201806130D0 (en) | Inhibitor compounds | |
| GB201621619D0 (en) | Inhibitor compounds | |
| GB201717530D0 (en) | New compounds | |
| GB201714049D0 (en) | New compounds | |
| GB201712289D0 (en) | New compounds | |
| GB201703273D0 (en) | Compounds | |
| GB201703283D0 (en) | Compounds |